凱普生物(300639.SZ)子公司獲得授予發明專利權通知書
格隆匯11月19日丨凱普生物(300639.SZ)公佈,公司的全資子公司廣州凱普醫藥科技有限公司(“凱普醫藥”)、廣州凱普生物科技有限公司(“廣州凱普”)和控股子公司廣州凱普醫學檢驗所有限公司(“廣州凱普檢驗所”)今日收到國家知識產權局下發的授予發明專利權通知書,涉一種重疊延伸PCR結合Sanger測序檢測耳聾易感基因突變的方法。
該發明公開了一種重疊延伸PCR結合Sanger測序檢測耳聾易感基因突變的方法。本方法基於一個用於擴增GJB2基因、SLC26A4基因、線粒體DNA和GJB3基因耳聾相關突變位點的引物組合。通過本發明建立的檢測方法,利用重疊延伸PCR結合Sanger測序方法檢測耳聾易感基因,可將13個PCR反應和13個測序反應減少至5個PCR反應和5個測序反應,大幅度降低成本及操作反應數,節約檢驗時間;同時通過該方法可以檢測GJB2基因、SLC26A4基因、線粒體DNA和GJB3基因的主要43個突變位點及其上下游序列,並可以發現擴增片段中新的變異位點,所以此檢測技術應用於耳聾易感基因突變檢測具有重要的臨牀意義。
該發明的取得不會對公司目前的經營狀況產生重大的影響,但有利於進一步完善公司的知識產權體系,充分發揮公司的知識產權優勢,促進公司產品結構的不斷豐富,提升公司的核心競爭力。
公司正依照辦理登記手續通知書的內容辦理登記手續。在按期辦理登記手續後,國家知識產權局將作出授予專利權的決定,頒發發明專利證書,並予以登記和公告,專利權自公告之日起生效,有效期自申請日起二十年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.